# US 2012/0251513 A1 · Antigen Specific Tolerogenic Antigen Presenting Cells and Related Uses Compositions, Methods and Systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251513 A1
- Document ID: US20120251513A1
- Status: Published application
- Kind: A1
- Application number: 13/496,658
- Filed: 2010-09-17
- Published: 2012-10-04
- Earliest claimed: 2009-09-18
- Inventors: Goran Hansson; Andreas Hermansson
- Web page: https://patentgrep.com/patent/US20120251513A1

## CPC

- A61K 39/0012: {Lipids; Lipoproteins}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 40/19: Dendritic cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/4285: {Lipids; Lipoproteins}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to antigen specific tolerogenic antigen presenting cells presenting antigenic portions of an autoantigen and to related compositions, methods and systems.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

A method of preparing an antigen-specific tolerogenic antigen-presenting cell comprising:
incubating at least one autoantigen, a fragment thereof, a derivative thereof or a precursor thereof, and an immunosuppressive cytokine with an antigen-presenting cell, such that an antigen-specific tolerogenic antigen presenting cell is produced.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the antigen presenting cell is isolated from peripheral blood, bone marrow or another hematopoietic or lymphoid organ.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the immunosuppressive cytokine comprises at least one cytokine of the transforming growth factor-beta (TGF-beta) superfamily, and/or interleukin-10.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the at least one cytokine comprises TGF-beta-2 and/or IL-10.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the incubating step comprising pulsing the antigen presenting cell with the autoantigen, the fragment thereof, or the derivative thereof.

### Claim 9 (depends on 4)

The method according to claim 4, wherein the incubating step comprising transfecting or electroporating a nucleic acid coding for the autoantigen, or portion thereof, the transfecting or electroporating resulting in the expression of the autoantigen or portion thereof.

### Claim 10

(canceled)

### Claim 11

A method of treating and/or preventing atherosclerosis, or a condition associated thereto, in an individual in need thereof, the method comprising administering to the individual an effective amount of an antigen-specific tolerogenic antigen-presenting cell adapted to present at least a portion of at least one autoantigen associated with atherosclerosis, the antigen-specific tolerogenic antigen-presenting cells being specific for the at least one autoantigen.

### Claim 12

(canceled)

### Claim 13 (depends on 11)

The method according to claim 11, wherein the effective amount is between about 1×106 to about 50×106 antigen-specific tolerogenic antigen-presenting cells.

### Claim 14

(canceled)

### Claim 15 (depends on 11)

The method according to claim 11, wherein the administering is performed in dosing intervals.

### Claim 16 (depends on 11)

The method according to claim 11, wherein the administering is performed by
intradermal, cutaneous, subcutaneous, nasal, peroral, intramuscular or intraperitoneal route.

### Claim 17 (depends on 11)

The method according to claim 11, wherein the administering is performed by intravenous route.

### Claim 18 (depends on 11)

The method according to claim 11, wherein the condition is coronary heart disease, myocardial infarction, stroke, and/or a peripheral artery disease.

### Claim 19

A pharmaceutical composition comprising an antigen-specific tolerogenic dendritic cell adapted to present of at least a portion of at least one autoantigen associated with atherosclerosis, the antigen-specific tolerogenic antigen-presenting cells being specific for the at least one autoantigen, together with a pharmaceutically acceptable vehicle.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the autoantigen is an oligopeptide derived from the ApoB100.

### Claim 22 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the antigen presenting cell is a dendritic cell, a monocyte, a macrophage, or a B lymphocyte.

### Claim 23 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the at least one autoantigen comprises ApoB100.

### Claim 24 (depends on 11)

The method according to claim 11, wherein the antigen presenting cell is a dendritic cell, a monocyte, a macrophage, or a B lymphocyte.

### Claim 25 (depends on 11)

The method according to claim 11, wherein the at least one autoantigen comprises ApoB100.
